192 related articles for article (PubMed ID: 18288635)
61. Cooperation between PU.1 and CAAT/enhancer-binding protein beta is necessary to induce the expression of the MD-2 gene.
Tissières P; Araud T; Ochoda A; Drifte G; Dunn-Siegrist I; Pugin J
J Biol Chem; 2009 Sep; 284(39):26261-72. PubMed ID: 19632992
[TBL] [Abstract][Full Text] [Related]
62. Cloning and characterization of the murine beta(3) integrin gene promoter: identification of an interleukin-4 responsive element and regulation by STAT-6.
McHugh KP; Kitazawa S; Teitelbaum SL; Ross FP
J Cell Biochem; 2001 Mar; 81(2):320-32. PubMed ID: 11241672
[TBL] [Abstract][Full Text] [Related]
63. RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation.
Kim JH; Kim K; Youn BU; Jin HM; Kim JY; Moon JB; Ko A; Seo SB; Lee KY; Kim N
Biochem J; 2011 Jun; 436(2):253-62. PubMed ID: 21413932
[TBL] [Abstract][Full Text] [Related]
64. MafB negatively regulates RANKL-mediated osteoclast differentiation.
Kim K; Kim JH; Lee J; Jin HM; Kook H; Kim KK; Lee SY; Kim N
Blood; 2007 Apr; 109(8):3253-9. PubMed ID: 17158225
[TBL] [Abstract][Full Text] [Related]
65. STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription.
Yang Y; Chung MR; Zhou S; Gong X; Xu H; Hong Y; Jin A; Huang X; Zou W; Dai Q; Jiang L
J Biol Chem; 2019 Oct; 294(42):15395-15407. PubMed ID: 31462535
[TBL] [Abstract][Full Text] [Related]
66. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
67. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
68. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).
Kim K; Lee SH; Ha Kim J; Choi Y; Kim N
Mol Endocrinol; 2008 Jan; 22(1):176-85. PubMed ID: 17885208
[TBL] [Abstract][Full Text] [Related]
69. Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion.
Shin CS; Her SJ; Kim JA; Kim DH; Kim SW; Kim SY; Kim HS; Park KH; Kim JG; Kitazawa R; Cheng SL; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2200-12. PubMed ID: 16294273
[TBL] [Abstract][Full Text] [Related]
70. Involvement of STAT-1 and ets family members in interferon-gamma induction of CD40 transcription in microglia/macrophages.
Nguyen VT; Benveniste EN
J Biol Chem; 2000 Aug; 275(31):23674-84. PubMed ID: 10823830
[TBL] [Abstract][Full Text] [Related]
71. ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1.
Rohatgi N; Zou W; Collins PL; Brestoff JR; Chen TH; Abu-Amer Y; Teitelbaum SL
Blood Adv; 2018 Oct; 2(19):2467-2477. PubMed ID: 30266822
[TBL] [Abstract][Full Text] [Related]
72. Tatarinan O, a lignin-like compound from the roots of Acorus tatarinowii Schott inhibits osteoclast differentiation through suppressing the expression of c-Fos and NFATc1.
Xu X; Liu N; Wang Y; Pan LC; Wu D; Peng Q; Zhang M; Wang HB; Sun WC
Int Immunopharmacol; 2016 May; 34():212-219. PubMed ID: 26971224
[TBL] [Abstract][Full Text] [Related]
73. MicroRNA-124 regulates osteoclast differentiation.
Lee Y; Kim HJ; Park CK; Kim YG; Lee HJ; Kim JY; Kim HH
Bone; 2013 Oct; 56(2):383-9. PubMed ID: 23867221
[TBL] [Abstract][Full Text] [Related]
74. c-Jun is a JNK-independent coactivator of the PU.1 transcription factor.
Behre G; Whitmarsh AJ; Coghlan MP; Hoang T; Carpenter CL; Zhang DE; Davis RJ; Tenen DG
J Biol Chem; 1999 Feb; 274(8):4939-46. PubMed ID: 9988737
[TBL] [Abstract][Full Text] [Related]
75. Lipopolysaccharide-dependent interaction between PU.1 and c-Jun determines production of lipocalin-type prostaglandin D synthase and prostaglandin D2 in macrophages.
Joo M; Kwon M; Cho YJ; Hu N; Pedchenko TV; Sadikot RT; Blackwell TS; Christman JW
Am J Physiol Lung Cell Mol Physiol; 2009 May; 296(5):L771-9. PubMed ID: 19181746
[TBL] [Abstract][Full Text] [Related]
76. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
77. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
78. Mitf-PU.1 interactions with the tartrate-resistant acid phosphatase gene promoter during osteoclast differentiation.
Partington GA; Fuller K; Chambers TJ; Pondel M
Bone; 2004 Feb; 34(2):237-45. PubMed ID: 14962802
[TBL] [Abstract][Full Text] [Related]
79. Transcriptional regulation of the cyclooxygenase-2 gene in macrophages by PU.1.
Joo M; Park GY; Wright JG; Blackwell TS; Atchison ML; Christman JW
J Biol Chem; 2004 Feb; 279(8):6658-65. PubMed ID: 14966110
[TBL] [Abstract][Full Text] [Related]
80. Osteon Myospalacem Baileyi attenuates osteoclast differentiation through RANKL induced NFAT pathways.
Cui Y; Zhao X; Mei L; Pei J; Wang S; Shao Y; Tao Y; Zhang X; Jiang L
J Ethnopharmacol; 2018 Mar; 213():65-71. PubMed ID: 29107144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
